(ChemotherapyAdvisor) – The first patient has been treated in a phase 2 clinical trial of intravenous delivery JX-594 in patients with advanced hepatocellular carcinoma (HCC), according to a July 25 press release from Jennerex Biotherapeutics (San Francisco, CA). This multinational, single-arm, open-label clinical trial will evaluate the efficacy and safety of intravenous treatment with JX-594 for patients with advanced HCC who have not received treatment with sorafenib – the current standard of care for this patient population.   

According to Jennerex, JX-594 is one of a series of first-in-class, targeted oncolytic poxvirus-based immunotherapies designed to selectively target and destroy cancer cells through 3 diverse mechanisms of action: lysis of cancer cells, destruction of tumor blood supply, and stimulation of the body’s immune response against cancer cells.

Previous clinical trials in several cancer types have demonstrated that JX-594, when delivered either directly into tumors or intravenously, is capable of inducing tumor shrinkage and/or cell death and is well-tolerated by patients.

Continue Reading

In this trial, the investigators aim to determine “the radiographic response rate based on modified RECIST and modified Choi criteria, followed by subsequent determination of progression-free survival (PFS) and overall survival (OS).”

The trial is being conducted at sites in South Korea, the United States, and Europe.

Press release

Trial information